ArticleParkinsonism & related disorders2023
Utilizing speech analysis to differentiate progressive supranuclear palsy from Parkinson's disease.
Article in Parkinsonism & related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 11 citations in OpenAlex.
- Voice and Speech in Atypical Parkinsonian Disorders.Movement disorders clinical practice · 2026Review
- A Machine Learning Approach to Voice-Based Parkinson Disease Screening Using Multiview Spectrogram and Speech Recognition Features: Diagnostic Study.JMIR medical informatics · 2026Article
- Clinical telemonitoring and telerehabilitation of cognition in rare neurological diseases: a scoping review.Journal of neurology · 2026Article
- Analytical validation of digital measure of intelligibility in progressive supranuclear palsy.Frontiers in neuroscience · 2026Article
- Improving access to care through transportation and internet use for patients with atypical parkinsonism: A pilot study.Clinical parkinsonism & related disorders · 2026Article
- From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy.Frontiers in neuroscience · 2026Review
- Dynamic Assessment of Fine Motor Control and Vocalization in Parkinson Disease Through a Smartphone App: Cross-Sectional Study of Time-Severity Interaction Effects.JMIR mHealth and uHealth · 2025Article
- Pathway to Regulatory Approval of Digital Health Technologies in Progressive Supranuclear Palsy: A Scoping Review.Brain sciences · 2025Review
- Speech and language biomarkers for Parkinson's disease prediction, early diagnosis and progression.NPJ Parkinson's disease · 2025Review
- Digital speech assessments and machine learning for differentiation of neurodegenerative diseases.Clinical parkinsonism & related disorders · 2025Article
- Digital assessment of speech in Huntington disease.Frontiers in neurology · 2024Article
- Harnessing Speech-Derived Digital Biomarkers to Detect and Quantify Cognitive Decline Severity in Older Adults.Gerontology · 2024Article
- Co-design of a voice-based app to monitor long COVID symptoms with its end-users: A mixed-method study.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
introductionDistinguishing Parkinson's disease (PD) from Progressive supranuclear palsy (PSP) at early disease stages is important for clinical trial enrollment and clinical care/prognostication.
methodsWe recruited 21 participants with PSP(n = 11) or PD(n = 10) with reliable caregivers. Standardized passage reading, counting, and sustained phonation were recorded on the BioDigit Home tablet (BioSensics LLC, Newton, MA USA), and speech features from the assessments were analyzed using the BioDigit Speech platform (BioSensics LLC, Newton, MA USA). An independent t-test was performed to compare each speech feature between PSP and PD participants. We also performed Spearman's correlations to evaluate associations between speech measures and clinical scores (e.g., PSP rating scales and MoCA). In addition, the model's performance in classifying PSP and PD was evaluated using Rainbow passage reading analysis.
resultsDuring Rainbow passage reading, PSP participants had a significantly slower articulation rate (2.45(0.49) vs 3.60(0.47) words/minute), lower speech-to-pause ratio (2.33(1.08) vs 3.67(1.18)), intelligibility dynamic time warping (DTW, 0.26(0.19) vs 0.53(0.26)), and similarity DTW (0.43(0.27) vs 0.67(0.13)) compared to PD participants. PSP participants also had longer pause times (17.24(5.47) vs 8.45(3.13) sec) and longer total signal times (52.44(6.67) vs (36.67(6.73) sec) when reading the passage. In terms of the phonation 'a', PSP participants showed a significant higher spectral entropy, spectral centroid, and spectral spread compared to PD participants and no differences were found for phonation 'e'. PD participants had more accurate reverse number counts than PSP participants (14.89(3.86) vs 7.36(4.67)). PSP Rating Scale (PSPRS) dysarthria (r = 0.79, p = 0.004) and bulbar item scores (r = 0.803, p = 0.005) were positively correlated with articulation rate in reverse number counts. Correct reverse number counts were positively correlated with total Montreal Cognitive Assessment scores (r = 0.703, p = 0.016). Machine learning models using passage reading-derived measures obtained an AUC of 0.93, and the sensitivity/specificity in correctly classifying PSP and PD participants were 0.95 and 0.90, respectively.
conclusionOur study demonstrates the feasibility of differentiating PSP from PD using a digital health technology platform. Further multi-center studies are needed to expand and validate our initial findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.